The human genome has generated hundreds of potential new drug targets. Validation of these targets with respect to their relevance to human disease has never been more important and is a vital step in ...
The "Rising Stars in Drug Metabolism and Transport 2025/2026" highlights the groundbreaking work of early-career researchers ...
The convergence of genomics, systems biology, and artificial intelligence is transforming the landscape of drug discovery. Modern genomic technologies now ...
TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing ...
Kelonia Therapeutics only started human testing of its in vivo CAR-T therapy for multiple myeloma in August, but already has ...
10don MSN
Rejuvenating the blood: New pharmacological strategy targets RhoA in hematopoietic stem cells
Aging is defined as the deterioration of function over time, and it is one of the main risk factors for numerous chronic ...
Vivan Therapeutics and the MRC Laboratory of Medical Sciences Announces a Pioneering Partnership to Explore How Specific Cancer Mutations, Diabetes & Diet Influence Drug Response London, UK [November ...
GlobalData on MSN
Regeneron and Tessera join forces to forge in vivo AATD gene therapy
Regeneron Pharmaceuticals has teamed up with Tessera Therapeutics to develop and commercialise Tessera’s rare disease in vivo ...
ONC001 is a first-in-class antibody-drug conjugate (ADC) designed to uniquely target CD64, a myeloid-restricted receptor pervasively expressed in CMML and M4/M5 acute myeloid leukemia, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback